Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

New Center for Tumor-Multiplying Diseases at Stanford Hospital

By March 16, 2012December 18th, 2023Awareness, NF2-SWN, Science & Research

On March 15, 2012, Stanford Hospital announced the launch of a new program, led by Dr. Steven Chang, to treat rare tumor-multiplying diseases.

 

Stanford’s program includes a team of 12 specialists in several fields: neurosurgery, epilepsy, neuro-ophthalmology, neuro-oncology, neuro-otology, neuro-interventional radiology, urology, and general surgery.

 

“The goal,” Chang said, “is to give cutting-edge care for conditions like Knodel’s, neurofibromatosis 2 (NF2) and others including another form of neurofibromatosis, schwannomatosis tuberous sclerosis, von Hippel-Lindau disease, Sturge Weber syndrome and hemorrhagic telangiectasia.”

 

Please click here to read more

Close Menu